Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
06 2019
Historique:
received: 08 03 2019
pubmed: 28 4 2019
medline: 1 5 2020
entrez: 28 4 2019
Statut: ppublish

Résumé

To compare 2-year safety and efficacy outcomes after Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH). One hundred eighty-one patients with BPH were assigned at random (2:1 ratio) to either Aquablation or TURP. Patients and follow-up assessors were blinded to treatment. Assessments included the International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function and uroflow. The focus of analysis was 2-year outcomes. At 2 years, IPSS scores improved by 14.7 points in the Aquablation group and 14.9 points in TURP (p = .8304, 95% CI for difference - 2.1 to 2.6 points). Two-year improvements in maximum flow rate (Q Two-year efficacy outcomes after TURP and Aquablation were similar, and the rate of surgical retreatment was low and similar to TURP. ClinicalTrials.gov no. NCT02505919. PROCEPT BioRobotics.

Identifiants

pubmed: 31028614
doi: 10.1007/s12325-019-00952-3
pii: 10.1007/s12325-019-00952-3
pmc: PMC6824383
doi:

Substances chimiques

Water 059QF0KO0R

Banques de données

ClinicalTrials.gov
['NCT02505919']
figshare
['10.6084/m9.figshare.7937555']

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1326-1336

Références

BJU Int. 1999 Feb;83(3):227-37
pubmed: 10233485
BJU Int. 2016 Jun;117(6):923-9
pubmed: 26477826
Can J Urol. 2017 Aug;24(4):8937-8940
pubmed: 28832316
Urology. 2018 Jan;111:1-9
pubmed: 29122620
Eur Urol. 2014 May;65(5):931-42
pubmed: 24331152
J Urol. 2013 Dec;190(6):2161-7
pubmed: 23764081
J Urol. 2011 May;185(5):1793-803
pubmed: 21420124
Adv Ther. 2018 Jun;35(6):832-838
pubmed: 29873008
BJU Int. 1999 Mar;83(4):410-5
pubmed: 10210562
Med Sci Monit. 2008 Jul;14(7):RA94-102
pubmed: 18591930
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
PLoS One. 2014 Jul 08;9(7):e101615
pubmed: 25003963
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
Br J Urol. 1996 Feb;77(2):233-47
pubmed: 8800892
J Urol. 2018 May;199(5):1252-1261
pubmed: 29360529
Int J Clin Pract. 2007 Sep;61(9):1437-45
pubmed: 17686091
Eur Urol. 2006 Nov;50(5):969-79; discussion 980
pubmed: 16469429

Auteurs

Peter Gilling (P)

Tauranga Urology Research, Tauranga, New Zealand. peter@urobop.co.nz.

Neil Barber (N)

Frimley Park Hospital, Frimley Health Foundation Trust, Surrey, UK.

Mohamed Bidair (M)

San Diego Clinical Trials, San Diego, CA, USA.

Paul Anderson (P)

Royal Melbourne Hospital, Melbourne, Australia.

Mark Sutton (M)

Houston Metro Urology, Houston, TX, USA.

Tev Aho (T)

Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.

Eugene Kramolowsky (E)

Virginia Urology, Richmond, VA, USA.

Andrew Thomas (A)

Princess of Wales Hospital, Bridgend, Wales, UK.

Barrett Cowan (B)

Urology Associates, P.C., Englewood, CO, USA.

Ronald P Kaufman (RP)

Albany Medical College, Albany, NY, USA.

Andrew Trainer (A)

Adult Pediatric Urology & Urogynecology, P.C., Omaha, NE, USA.

Andrew Arther (A)

Adult Pediatric Urology & Urogynecology, P.C., Omaha, NE, USA.

Gopal Badlani (G)

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Mark Plante (M)

University of Vermont Medical Center, Burlington, VT, USA.

Mihir Desai (M)

Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Leo Doumanian (L)

Institute of Urology, University of Southern California, Los Angeles, CA, USA.

Alexis E Te (AE)

Weill Cornell Medical College, New York, NY, USA.

Mark DeGuenther (M)

Urology Centers of Alabama, Birmingham, AL, USA.

Claus Roehrborn (C)

Department of Urology, UT Southwestern Medical Center, University of Texas Southwestern, Dallas, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH